Strategies to improve survival of patients with intrahepatic cholangiocarcinoma undergoing liver transplantation
Rahul Gupta, Jyoti Gupta – 20 December 2016
Reply:
Benjamin Lelouvier, Florence Servant, Michael Courtney, Rémy Burcelin, Jacques Amar – 20 December 2016
The core domain of hepatitis C virus glycoprotein E2 generates potent cross‐neutralizing antibodies in guinea pigs
Patricia T. Vietheer, Irene Boo, Jun Gu, Kathleen McCaffrey, Stirling Edwards, Catherine Owczarek, Matthew P. Hardy, Louis Fabri, Rob J. Center, Pantelis Poumbourios, Heidi E. Drummer – 20 December 2016 – A vaccine that prevents hepatitis C virus (HCV) infection is urgently needed to support an emerging global elimination program. However, vaccine development has been confounded because of HCV's high degree of antigenic variability and the preferential induction of type‐specific immune responses with limited potency against heterologous viral strains and genotypes.
New therapeutic concepts in bile acid transport and signaling for management of cholestasis
Michael Trauner, Claudia Daniela Fuchs, Emina Halilbasic, Gustav Paumgartner – 20 December 2016 – The identification of the key regulators of bile acid (BA) synthesis and transport within the enterohepatic circulation has revealed potential targets for pharmacological therapies of cholestatic liver diseases.
New therapeutic concepts in bile acid transport and signaling for management of cholestasis
Michael Trauner, Claudia Daniela Fuchs, Emina Halilbasic, Gustav Paumgartner – 20 December 2016 – The identification of the key regulators of bile acid (BA) synthesis and transport within the enterohepatic circulation has revealed potential targets for pharmacological therapies of cholestatic liver diseases.
Ignore reality but not the consequences of its ignorance: Broaden guidelines in surgery of hepatocellular carcinoma
Demetrios Moris, Evangelos Felekouras – 20 December 2016
Reply:
Gonzalo Sapisochin, Jordi Bruix – 20 December 2016
Screening for hepatocellular carcinoma: What is missing?
Neil J. Mehta, Aygul Dogan Celik, Marion G. Peters – 19 December 2016 – While there are guidelines from all major liver societies for the screening and management of hepatocellular carcinoma (HCC), many issues remain surrounding the actual practice of screening. This review discusses how to diagnose and screen HCC and more importantly, how well we diagnose and screen for HCC. Improved survival and outcomes after HCC diagnosis depend upon accurate diagnosis of cirrhosis and the timeliness of screening.
Human immunodeficiency virus–infected and uninfected adults with non–genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection
Jennifer C. Price, Yifei Ma, Rebecca Scherzer, Natalie Korn, Kyle Tillinghast, Marion G. Peters, Susan M. Noworolski, Phyllis C. Tien – 16 December 2016 – Hepatic steatosis (HS) is common in individuals with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections, but the independent contributions of HCV and HIV to HS are unclear.
Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease
Fernando Bril, Diana Barb, Paola Portillo‐Sanchez, Diane Biernacki, Romina Lomonaco, Amitabh Suman, Michelle H. Weber, Jeffrey T. Budd, Maria E. Lupi, Kenneth Cusi – 16 December 2016 – The cut‐off point of intrahepatic triglyceride (IHTG) content to define nonalcoholic fatty liver disease (NAFLD) by proton magnetic resonance spectroscopy (1H‐MRS) was established based on the 95th percentile in a group of healthy individuals (i.e., ≥5.56%).